BioNTech
Financials
Estimates*
EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 482m | 19.0b | 17.3b | 3.8b | 2.7b | 2.7b | 2.8b |
% growth | 344 % | 3834 % | (9 %) | (78 %) | (28 %) | (1 %) | 2 % |
EBITDA | (42.1m) | 15.0b | 13.1b | 1.2b | (949m) | (1.0b) | (1.0b) |
% EBITDA margin | (9 %) | 79 % | 76 % | 30 % | (35 %) | (38 %) | (37 %) |
Profit | 15.2m | 10.3b | 9.4b | 930m | (523m) | (636m) | (681m) |
% profit margin | 3 % | 54 % | 55 % | 24 % | (19 %) | (23 %) | (25 %) |
EV / revenue | 31.0x | 2.8x | 1.2x | 3.0x | 2.4x | 2.6x | 2.9x |
EV / EBITDA | -354.8x | 3.6x | 1.6x | 9.7x | -6.8x | -7.0x | -7.7x |
R&D budget | 645m | <1m | <1m | 1.8b | - | - | - |
R&D % of revenue | 134 % | - | - | 47 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | N/A | Seed | |
N/A | Spinout | ||
* | €225m | Series A | |
* | €80.0m Valuation: €2.5b 18.3x EV/LTM Revenues -97.2x EV/LTM EBITDA | Growth Equity VC | |
* | $325m Valuation: $2.5b 16.6x EV/LTM Revenues -88.4x EV/LTM EBITDA | Series B | |
$55.0m | Grant | ||
N/A | $150m Valuation: $3.4b 22.6x EV/LTM Revenues -120.2x EV/LTM EBITDA | IPO | |
$55.8m | Debt | ||
$250m | Private Placement VC | ||
€100m | Debt | ||
€375m | Grant | ||
* | N/A | $150m | Post IPO Equity |
* | $145m | Grant | |
Total Funding | $1.5b |
Recent News about BioNTech
EditBioNTech is a biotechnology company focused on developing and commercializing innovative immunotherapies for the treatment of cancer and infectious diseases. Founded by scientists and physicians, BioNTech operates in the biopharmaceutical market, serving patients worldwide. The company leverages its expertise in mRNA technology to create personalized vaccines and therapies that stimulate the immune system to fight diseases. BioNTech collaborates with global partners to advance its diversified clinical pipeline, which includes treatments for various cancers and infectious diseases with high unmet medical needs. The company generates revenue through the development and commercialization of its therapies, as well as through partnerships and potential royalty payments from its lead cell therapy candidates. BioNTech is committed to equitable access to its innovative medicines, aiming to address pressing global health challenges.
Keywords: mRNA technology, immunotherapies, cancer treatment, infectious diseases, personalized vaccines, biopharmaceutical, clinical pipeline, global partnerships, innovative medicines, equitable access.